Global Japanese Encephalitis Virus Vaccine Market Size By Type (Inactivated Vaccine, Live Attenuated Vaccine), By Application (Public, Private), By Region, And Segment Forecasts, 2023 to 2032

The Global Japanese Encephalitis Virus (JEV) Vaccine Market was valued at USD 480 million in 2023 and is anticipated to reach USD 768 million by 2031, expanding at a CAGR of 6.2% during the forecast period (2023–2031). The growth is driven by the increasing prevalence of Japanese encephalitis (JE) in endemic regions, rising immunization initiatives by public health authorities, and growing awareness about vaccine-preventable diseases. Japanese encephalitis remains a significant public health concern across Asia-Pacific and parts of the Western Pacific, leading to the consistent demand for preventive vaccination.

Drivers:

1. Rising Incidence in Endemic Regions:

Countries like India, China, Nepal, and Vietnam continue to report substantial JE cases, creating a pressing need for widespread vaccination programs.

2. Government and NGO Vaccination Campaigns:

Global organizations such as the WHO and Gavi, in collaboration with national governments, are promoting mass immunization drives, especially targeting children in rural and semi-urban areas.

3. Advancements in Vaccine Formulations:

Improvements in vaccine development, including inactivated Vero cell-derived vaccines and recombinant live attenuated vaccines, are enhancing safety profiles and immunogenicity.

Restraints:

1. Limited Awareness in Non-Endemic Regions:

Due to the concentration of JE in certain geographic areas, awareness and investment in the vaccine outside of those regions remain limited.

2. Logistical Challenges in Rural Immunization:

Rural healthcare infrastructure inadequacies and challenges in cold chain management can hinder vaccine distribution in high-risk areas.

Opportunity:

1. Travel Vaccination Market Expansion:

Increasing global travel to endemic areas is boosting the demand for JE vaccines among tourists and military personnel.

2. Pipeline Vaccine Developments:

The development of next-generation vaccines, including single-dose regimens and combination vaccines, offers lucrative potential for market players.

3. Strategic Partnerships in Asia-Pacific:

Collaborations between local governments and international biopharmaceutical companies present opportunities for market penetration and expansion.

Market by System Type Insights:

The Inactivated Vero Cell-Derived Vaccine segment accounted for the largest market share in 2023. These vaccines are widely accepted due to their high efficacy and minimal side effects, making them ideal for both national immunization programs and private healthcare providers. The Live Attenuated Vaccine segment is expected to grow steadily, driven by its lower cost and ease of administration in large-scale campaigns.

Market by End-use Insights:

The Public Health Sector segment dominated the end-use market in 2023, fueled by large-scale government-led immunization campaigns. Meanwhile, the Private Clinics and Hospitals segment is gaining traction, especially in urban centers and among travelers seeking JE protection. This segment is expected to grow notably due to rising healthcare expenditure and awareness.

Market by Regional Insights:

The Asia-Pacific region led the global Japanese encephalitis virus vaccine market in 2023, with countries like India, China, and Southeast Asian nations being the primary contributors due to endemic status and high disease burden. The North America and Europe markets are also expanding, primarily driven by travel-related vaccinations and increased awareness among travelers and military personnel.

Competitive Scenario:

Key players in the Global Japanese Encephalitis Virus Vaccine Market include:

Chengdu Institute of Biological Products

Sanofi Pasteur

Bharat Biotech

Valneva SE

Biological E. Limited

Lanzhou Institute of Biological Products

These companies are actively involved in strategic product launches, distribution partnerships, and collaborations with global health organizations. For instance:

In 2023, Sanofi Pasteur expanded its vaccine outreach programs in Southeast Asia with WHO support.

In 2024, Valneva SE reported Phase III trial success of a new recombinant JE vaccine tailored for travelers.

In 2025, Bharat Biotech partnered with the Indian government to expand the supply of its JE vaccine in public immunization programs.

Scope of Work – Global Japanese Encephalitis Virus Vaccine Market

Key Market Developments:

March 2023: WHO expanded JE vaccination guidelines, including broader age groups for endemic regions.

July 2024: Bharat Biotech announced its second manufacturing unit for JE vaccines in India to scale up supply.

February 2025: Valneva SE received regulatory approval in the U.S. for its JE vaccine for military personnel and travelers.

FAQs:

1) What is the current market size of the Global Japanese Encephalitis Virus Vaccine Market?

The market was valued at USD 480 million in 2023.

2) What is the major growth driver of the Global Japanese Encephalitis Virus Vaccine Market?

Rising incidence of Japanese encephalitis in endemic regions and increasing immunization initiatives.

3) Which is the largest region during the forecast period in the Global Japanese Encephalitis Virus Vaccine Market?

Asia-Pacific remains the largest region due to the high disease burden and strong government-led vaccination programs.

4) Which segment accounted for the largest market share in Global Japanese Encephalitis Virus Vaccine Market?

The Inactivated Vero Cell-Derived Vaccine segment led the market in 2023.

5) Who are the key market players in the Global Japanese Encephalitis Virus Vaccine Market?

Key players include Sanofi Pasteur, Chengdu Institute of Biological Products, Bharat Biotech, Valneva SE, and Biological E. Limited.